Talassemi i sverige: Behandlingsmål och uppföljning varierar kraftigt

Lakartidningen

Volumn 103, Issue 47, 2006, Pages 3714-3715

  Oehmichen, Marie ^a   Ljung, Rolf ^b  

^a Barn Och Ungdomscentrum ^*  (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON;

BLOOD; BLOOD TRANSFUSION; CHILD; CLINICAL PRACTICE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; QUESTIONNAIRE; SHORT SURVEY; SWEDEN; THALASSEMIA;

BLOOD TRANSFUSION; CHILD; FERRITINS; FOLLOW-UP STUDIES; HUMANS; IRON; PHYSICIAN'S PRACTICE PATTERNS; QUALITY ASSURANCE, HEALTH CARE; QUESTIONNAIRES; SWEDEN; THALASSEMIA;

EID: 33751569852     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Thalassemia International Federation. http://www.thalassaemia.org.cy/
2. Sandström L, Ljung R, Henter JI, Elinder G. Talassemi på väg in i landet. Ny patientgrupp på svenska barnkliniker. Läkartidningen 1996;93:26-30.
3. Eleftheriou A. About thalassaemia. Thalassemia International Federation Publications; 2003. p.62-75. http://www.thalassaemia.org.cy/books/abouttha.pdf
4. Hoffbrand A, Cohen A. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
5. Anderson L, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-20.
6. Wonke B. Clinical management of β-thalassemia major. Semin Hematol 2001;38:350-9.